Mark Yarchoan, MD, is an Associate Professor of Medical Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, Maryland. He is a leading clinician–scientist in the treatment of primary liver cancers and directs an NCI-funded laboratory focused on developing innovative immunotherapies, with a particular emphasis on neoantigen-targeted vaccines.

Dr. Yarchoan has served as Principal Investigator on multiple landmark clinical trials, including the first studies of a personalized neoantigen vaccine for hepatocellular carcinoma (HCC), neoadjuvant anti-PD-1 immunotherapy in HCC, and a neoantigen-specific T-cell vaccine for fibrolamellar hepatocellular carcinoma (FLC). He contributes his clinical expertise to numerous guideline committees, including the American Society of Clinical Oncology (ASCO), American Association for the Study of Liver Diseases (AASLD), the Fibrolamellar Cancer Foundation, and as co-chair of the upcoming HCC-BEACON North American Liver Cancer System.

His research focuses on elucidating mechanisms of response, resistance, and toxicity to immune checkpoint inhibitors, and on overcoming immune resistance through therapeutic cancer vaccines and other novel immune-based strategies. He is a scientific co-founder of Adventris Pharmaceuticals, a company spun out from his laboratory that is initiating a phase 1/2 trial of a novel cancer vaccine.

Dr. Yarchoan has been first or corresponding author on high-impact publications in New England Journal of Medicine, Nature Medicine, Nature Cancer, Nature Immunology, and Journal of Clinical Investigation. His work has been recognized with multiple honors, including the Cholangiocarcinoma Foundation’s Mark R. Clements Award, the Blue Faery Award for Excellence in Liver Cancer Research, and the Conquer Cancer Foundation ASCO Career Development Award. Through his combined roles as clinician, investigator, and mentor, he is committed to translating scientific discoveries into durable, effective therapies for patients with liver cancer worldwide.